Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
30. Januar 2019 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation
26. Dezember 2018 07:30 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Neos Therapeutics Announces Realignment of Commercial Organization
30. November 2018 07:30 ET
|
Neos Therapeutics, Inc.
– Strategic assessment leads to new salesforce structure and is expected to accelerate path to profitability – – Company to host conference call today at 8:30am ET – DALLAS and FORT WORTH, Texas,...
Neos Therapeutics Reports Third Quarter 2018 Financial Results
09. November 2018 07:00 ET
|
Neos Therapeutics, Inc.
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical...
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
06. November 2018 09:21 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and...
Neos Therapeutics Announces Proposed Offering of Common Stock
05. November 2018 16:03 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and...
Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
02. November 2018 07:30 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the opening...
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
24. Oktober 2018 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release...
Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)
23. Oktober 2018 08:00 ET
|
Neos Therapeutics, Inc.
Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options Development Strategy Leverages Neos’ Modified-Release...
Neos Therapeutics to Present at the Cantor Global Healthcare Conference
26. September 2018 07:30 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully integrated pharmaceutical company focused on developing, manufacturing and...